MedTrace Logo

Inhaled Steroids and Control of Severe Asthma

NCT01197482 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2020-11-10

No results posted yet for this study

Summary

Investigational device: AKITA 2 device versus conventional metered-dose inhaler (MDI)

Objectives: To explore if inhalative fluticasone application by means of the AKITA technology would result in a better symptom control in patients with severe persistent asthma as compared to inhalative application of fluticasone by a conventional MDI.

Study design: open label, cross-over (one AKITA, one MDI arm)

Patients: 20 Patients with severe persistent asthma

Conditions

  • Severe Persistent Asthma

Sponsors & Collaborators

  • Activaero GmbH

    collaborator INDUSTRY

  • University of Giessen

    lead OTHER

Principal Investigators

  • Andreas Guenther, MD · University of Giessen

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2018-12-28
Completion
2018-12-28

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01197482 on ClinicalTrials.gov